George D. Demetri
乔治·德梅特里
MD
Senior Vice President for Experimental Therapeutics; Director, Ludwig Center at Harvard实验治疗学高级副总裁；哈佛路德维希中心主任
👥Biography 个人简介
George Demetri is one of the world's foremost authorities on gastrointestinal stromal tumors (GIST) and soft tissue sarcomas. He led pivotal clinical trials establishing imatinib (Gleevec) as the first effective molecularly targeted therapy for GIST, fundamentally transforming the prognosis of a previously lethal disease. His laboratory and clinical research programs span KIT/PDGFRA oncogenesis, resistance mechanisms to TKI therapy, and novel combinatorial strategies for sarcoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Imatinib for GIST — Landmark Phase II/III Trials
Led the North American Phase II trial of imatinib in metastatic GIST (NEJM 2002) demonstrating a 54% objective response rate in a tumor previously refractory to all chemotherapy, establishing imatinib as standard of care and validating oncogene-targeted therapy in solid tumors.
Sunitinib in Imatinib-Refractory GIST
Led the global Phase III trial demonstrating that sunitinib significantly improved time to tumor progression compared to placebo in imatinib-resistant or intolerant GIST patients, establishing the second-line treatment standard.
Regorafenib Third-Line GIST (GRID Trial)
Co-led the GRID phase III trial showing regorafenib improved progression-free survival in patients with GIST after failure of imatinib and sunitinib, establishing the third-line standard of care.
Representative Works 代表性著作
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
New England Journal of Medicine (2002)
Landmark Phase II trial demonstrating dramatic activity of imatinib in metastatic GIST, transforming treatment paradigm for this disease.
Sunitinib Malate for Gastrointestinal Stromal Tumour after Imatinib Failure: Randomised Controlled Trial
The Lancet (2006)
Phase III trial establishing sunitinib as second-line standard of care in imatinib-refractory GIST.
Regorafenib for Metastatic Gastrointestinal Stromal Tumours after Failure of Imatinib and Sunitinib (GRID): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial
The Lancet (2013)
Phase III GRID trial establishing regorafenib as third-line therapy for advanced GIST.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 乔治·德梅特里 的研究动态
Follow George D. Demetri's research updates
留下邮箱，当我们发布与 George D. Demetri（Dana-Farber Cancer Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment